232 related articles for article (PubMed ID: 26700354)
21. Breast MRI BI-RADS assessments and abnormal interpretation rates by clinical indication in US community practices.
Lee CI; Ichikawa L; Rochelle MC; Kerlikowske K; Miglioretti DL; Sprague BL; DeMartini WB; Wernli KJ; Joe BN; Yankaskas BC; Lehman CD
Acad Radiol; 2014 Nov; 21(11):1370-6. PubMed ID: 25126973
[TBL] [Abstract][Full Text] [Related]
22. Growing BI-RADS category 3 lesions on follow-up breast ultrasound: malignancy rates and worrisome features.
Ha SM; Chae EY; Cha JH; Shin HJ; Choi WJ; Kim HH
Br J Radiol; 2018 Jul; 91(1087):20170787. PubMed ID: 29658793
[TBL] [Abstract][Full Text] [Related]
23. Prevalence and Predictive Value of BI-RADS 3, 4, and 5 Lesions Detected on Breast MRI: Correlation with Study Indication.
Chikarmane SA; Tai R; Meyer JE; Giess CS
Acad Radiol; 2017 Apr; 24(4):435-441. PubMed ID: 27955878
[TBL] [Abstract][Full Text] [Related]
24. Tomosynthesis in the Diagnostic Setting: Changing Rates of BI-RADS Final Assessment over Time.
Raghu M; Durand MA; Andrejeva L; Goehler A; Michalski MH; Geisel JL; Hooley RJ; Horvath LJ; Butler R; Forman HP; Philpotts LE
Radiology; 2016 Oct; 281(1):54-61. PubMed ID: 27139264
[TBL] [Abstract][Full Text] [Related]
25. Focal Breast Lesions in Clinical CT Examinations of the Chest: A Retrospective Analysis.
Krug KB; Houbois C; Grinstein O; Borggrefe J; Puesken M; Hanstein B; Malter W; Maintz D; Hellmich M
Rofo; 2017 Oct; 189(10):977-989. PubMed ID: 28683503
[No Abstract] [Full Text] [Related]
26. Probably benign lesions at screening breast US in a population with elevated risk: prevalence and rate of malignancy in the ACRIN 6666 trial.
Barr RG; Zhang Z; Cormack JB; Mendelson EB; Berg WA
Radiology; 2013 Dec; 269(3):701-12. PubMed ID: 23962417
[TBL] [Abstract][Full Text] [Related]
27. The value of breast MRI for BI-RADS category 4B mammographic microcalcification: based on the 5
Eun NL; Son EJ; Gweon HM; Youk JH; Kim JA
Clin Radiol; 2018 Aug; 73(8):750-755. PubMed ID: 29853301
[TBL] [Abstract][Full Text] [Related]
28. MRI in the Assessment of BI-RADS® 4 lesions.
Leithner D; Wengert G; Helbich T; Morris E; Pinker K
Top Magn Reson Imaging; 2017 Oct; 26(5):191-199. PubMed ID: 28961568
[TBL] [Abstract][Full Text] [Related]
29. Outcomes of unconventional utilization of BI-RADS category 3 assessment at opportunistic screening.
Altas H; Tureli D; Cengic I; Kucukkaya F; Aribal E; Kaya H
Acta Radiol; 2016 Nov; 57(11):1304-1309. PubMed ID: 26019241
[TBL] [Abstract][Full Text] [Related]
30. Reassessment and Follow-Up Results of BI-RADS Category 3 Lesions Detected on Screening Breast Ultrasound.
Chae EY; Cha JH; Shin HJ; Choi WJ; Kim HH
AJR Am J Roentgenol; 2016 Mar; 206(3):666-72. PubMed ID: 26901026
[TBL] [Abstract][Full Text] [Related]
31. Is a one-year follow-up an efficient method for better management of MRI BI-RADS(®) 3 lesions?
Boisserie-Lacroix M; Ziadé C; Hurtevent-Labrot G; Ferron S; Brouste V; Lippa N
Breast; 2016 Jun; 27():1-7. PubMed ID: 27212693
[TBL] [Abstract][Full Text] [Related]
32. The breast imaging reporting and data system: positive predictive value of mammographic features and final assessment categories.
Liberman L; Abramson AF; Squires FB; Glassman JR; Morris EA; Dershaw DD
AJR Am J Roentgenol; 1998 Jul; 171(1):35-40. PubMed ID: 9648759
[TBL] [Abstract][Full Text] [Related]
33. MRI for the assessment of malignancy in BI-RADS 4 mammographic microcalcifications.
Bennani-Baiti B; Dietzel M; Baltzer PA
PLoS One; 2017; 12(11):e0188679. PubMed ID: 29190656
[TBL] [Abstract][Full Text] [Related]
34. ACR BI-RADS Assessment Category 4 Subdivisions in Diagnostic Mammography: Utilization and Outcomes in the National Mammography Database.
Elezaby M; Li G; Bhargavan-Chatfield M; Burnside ES; DeMartini WB
Radiology; 2018 May; 287(2):416-422. PubMed ID: 29315061
[TBL] [Abstract][Full Text] [Related]
35. Use of BI-RADS 3-probably benign category in the American College of Radiology Imaging Network Digital Mammographic Imaging Screening Trial.
Baum JK; Hanna LG; Acharyya S; Mahoney MC; Conant EF; Bassett LW; Pisano ED
Radiology; 2011 Jul; 260(1):61-7. PubMed ID: 21502382
[TBL] [Abstract][Full Text] [Related]
36. Management for BI-RADS category 3 lesions detected in preoperative breast MR imaging of breast cancer patients.
Gweon HM; Cho N; Kim SY; Koo HR; Seo M; Chu A; Son EJ
Eur Radiol; 2017 Aug; 27(8):3211-3216. PubMed ID: 28083693
[TBL] [Abstract][Full Text] [Related]
37. Longitudinal measurement of clinical mammographic breast density to improve estimation of breast cancer risk.
Kerlikowske K; Ichikawa L; Miglioretti DL; Buist DS; Vacek PM; Smith-Bindman R; Yankaskas B; Carney PA; Ballard-Barbash R;
J Natl Cancer Inst; 2007 Mar; 99(5):386-95. PubMed ID: 17341730
[TBL] [Abstract][Full Text] [Related]
38. Revisiting the mammographic follow-up of BI-RADS category 3 lesions.
Varas X; Leborgne JH; Leborgne F; Mezzera J; Jaumandreu S; Leborgne F
AJR Am J Roentgenol; 2002 Sep; 179(3):691-5. PubMed ID: 12185047
[TBL] [Abstract][Full Text] [Related]
39. Follow-up frequency and compliance in women with probably benign findings on breast magnetic resonance imaging.
Marshall AL; Domchek SM; Weinstein SP
Acad Radiol; 2012 Apr; 19(4):406-11. PubMed ID: 22227041
[TBL] [Abstract][Full Text] [Related]
40. Patient compliance and diagnostic yield of 18-month unilateral follow-up in surveillance of probably benign mammographic lesions.
Chung CS; Giess CS; Gombos EC; Frost EP; Yeh ED; Raza S; Birdwell RL
AJR Am J Roentgenol; 2014 Apr; 202(4):922-7. PubMed ID: 24660725
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
